IntelliCell Biosciences Stem Cells Used to Successfully Treat Bell's Palsy and Type I Diabetes Patient
09 October 2013 - 11:57PM
Marketwired
IntelliCell Biosciences Stem Cells Used to Successfully Treat
Bell's Palsy and Type I Diabetes Patient
NEW YORK, NY--(Marketwired - Oct 9, 2013) - IntelliCell
Biosciences, Inc. (OTCQB: SVFC), a regenerative medicine company
utilizing adult autologous vascular cells (SVCs) derived from the
blood vessels, announced today that it has supplied its cellular
product, stromal vascular fraction cells ("SVFC"), to Regen Medical
PC for the successful treatment of a Type I diabetic patient, who
had developed bilateral permanent Bell's palsy.
Previous medical history stated neither the patient's diabetes
nor Bell's palsy had improved following 6 months of multiple
congenital treatments. Following the unsuccessful treatments,
the patient was remitted to the care of Dr. Steven Victor of ReGen
Medical PC. Under the care of Dr. Victor, the patient received two
treatments of ReGen Medical's proprietary stem cell applications
spaced 6 months apart. The result was a total resolution of
the Bell's palsy. The patient also noted that his insulin
requirements for his Type I diabetes was reduced from 60 Units of
Insulin daily to 5-10 Units of Insulin daily.
Dr. Steven Victor, Chairman and CEO of IntelliCell Biosciences,
commented, "This was a clinical treatment utilizing IntelliCell's
SVFC method, which addressed an unmet clinical need. If not
for our successful treatments, this patient was going to have to
undergo corrective surgery of his eye and face and retire from his
job due to slurred speech. Prior to our treatment the patient
had been treated at some of most respected Medical Centers without
getting any positive results. It is rewarding to have been
part of a treatment for a patient where our cellular product helped
change his quality of life. IntelliCell firmly believes that
the future of medicine will entail utilizing cellular therapy for
previously unmet clinical needs. Additionally, we were excited
to see the patient's insulin requirements reduced and we are
looking into the possibility of our cellular product for future
treatments of Diabetes Type I and Type II."
Bell's palsy is a form of facial paralysis resulting from a
dysfunction of the cranial nerve VII (the facial nerve) causing an
inability to control facial muscles on the affected side. Major
complications of the condition are chronic loss of taste (ageusia),
chronic facial spasms, facial pain and corneal infections.
Diabetes is a group of metabolic diseases in which a person has
high blood sugar, either because the pancreas does not produce
enough insulin, or because cells do not respond to the insulin that
is produced. Type I Diabetes results from the body's failure to
produce insulin, and currently requires the person to inject
insulin or wear an insulin pump. All forms of diabetes increase the
risk of long-term complications. The major long-term
complications relate to damage to blood vessels. Diabetes also
doubles the risk of cardiovascular disease.
"IntelliCell believes that we possess a paradigm shifting
discovery that will change the manner in which patients are
treated," Dr. Victor continued. "We are confident that our
relationships with the FDA and other governing bodies will allow us
to rapidly expand the amounts of patients that we can treat using
our SFV therapy."
About IntelliCell Biosciences IntelliCell is a pioneering
regenerative medicine company focused on the expanding regenerative
medical markets using adult autologous stromal vascular fraction
cells (SVFCs) derived from the blood vessels in the adult adipose
tissue. IntelliCell Biosciences has developed its own patented
technology and protocol to separate adult autologous vascular cells
from adipose tissue without the use of enzymes. IntelliCell will
also be seeking to develop technology-licensing agreements with
technology developers, universities, and international business
entities.
Forward-Looking Statements Certain statements set forth in this
press release constitute "forward-looking statements."
Forward-looking statements include, without limitation, any
statement that may predict, forecast, indicate, or imply future
results, performance or achievements, and may contain the words
"estimate," "project," "intend," "forecast," "anticipate," "plan,"
"planning," "expect," "believe," "will likely," "will reach," "will
change," "will soon," "should," "could," "would," "may," "can" or
words or expressions of similar meaning. Such statements are not
guarantees of future performance and are subject to risks and
uncertainties that could cause the company's actual results and
financial position to differ materially from those included within
the forward-looking statements. Forward-looking statements involve
risks and uncertainties, including those relating to the Company's
ability to grow its business. Actual results may differ materially
from the results predicted and reported results should not be
considered as an indication of future performance. The potential
risks and uncertainties include, among others, the Company's
limited operating history, the limited financial resources,
domestic or global economic conditions, activities of competitors
and the presence of new or additional competition, and changes in
Federal or State laws. More information about the potential factors
that could affect the Company's business and financial results is
included in the Company's filings, available via the United States
Securities and Exchange Commission.
Contacts: IntelliCell Biosciences, Inc. Investor Relations
Contact: Anna Rhodes Email Contact (646) 576-8308